This site is intended for health professionals only

Published on 6 February 2009

Share this story:
Twitter
LinkedIn

Tibotec submits application to US FDA for Intelence

teaser

Tibotec have announced it has submitted an application to the US Food and Drug Administration (FDA) seeking traditional approval for Intelence (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI).

The application for traditional approval includes 48-week data from two phase 3 studies known as DUET-1 and DUET-2. Intelence is currently marketed in the US by Tibotec Therapeutics, a division of Centocor Ortho Biotech Products, LP.

Intelence received accelerated approval in January 2008. As part of the post-marketing commitment, Tibotec is required to submit 48-week data from the DUET studies to the FDA in order for it to consider traditional approval for Intelence.

Intelence, in combination with other antiretroviral agents is currently indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a NNRTI and other antiretroviral (ARV) agents.

This indication is based on week 24 analyses from two randomised, double-blind, placebo-controlled trials of Intelence.

Both studies were conducted in clinically advanced, three-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults.The following points should be considered when initiating therapy with Intelence:

Treatment history and when available resistance testing should guide the use of Intelence.

  • The use of other active antiretroviral agents with Intelence is associated with an increased likelihood of treatment response.
  • In patients who have experienced virologic failure on a NNRTI-containing regimen, do not use Intelence in combination with only N[t]RTIs.
  • The risks and benefits of Intelence have not been established in pediatric patients or in treatment-naïve adult patients.

For more details please click on the link below:

Johnson & Johnson



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn